Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (8989)	8/25/2003 9:39:17 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

same seems to hold true for Periostat Periostat is truly unique in its patent position. The underlying drug is an antibiotic (doxycycline) that has been generic for decades. Here it is being prescribed in a dose lower than is used for antibiotics, indeed a dose form where no generic is presently available. Collagenex has a use patent covering this low-dose use, and they are not unreasonably arguing that the only purpose of a low-dose generic would be to compete with their patented use. Note that the drug is not acting as an antibiotic at these dose levels - instead it is likely acting to stabilize collagen by inhibiting collagenase. Peter